Skip to main content
Premium Trial:

Request an Annual Quote

Enzon, Micromet End Antibody Drug R&D Partnership

NEW YORK, Nov. 28 (GenomeWeb News) - Enzon Pharmaceuticals and Micromet will end their collaboration to identify and develop antibody-based therapeutics for inflammatory and autoimmune diseases, the companies said today.


The decision was made after Enzon decided to redirect its efforts onto new business objectives, including a greater focus on cancer, the companies said. Enzon and Micromet had been collaborating since April 2002.


The companies said that the termination of their collaboration does not affect their other agreements, including a cross-license agreement between the parties and a marketing agreement under which Micromet is the exclusive marketer of the companies' combined intellectual property estate in the field of single-chain antibody technology.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.